Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Teverelix Trifluoroacetate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Teverelix (teverelix trifluoroacetate) is an decapeptide, long-acting GnRH antagonist which has the potential to be the first hormone therapy specifically approved to treat advanced prostate cancer patients with a history of cardiovascular disease.
Product Name : Teverelix
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2023
Lead Product(s) : Teverelix Trifluoroacetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
